Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model

Cancer Gene Therapy

Volumn 12, Issue 2, 2005, Pages 175-184

  Lee, Che Hsin ^a   Wu, Chao Liang ^a   Shiau, Ai Li ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Antiangiogenesis; Salmonella choleraesuis; Thrombospondin 1; Tumor targeted

Indexed keywords

ANGIOGENESIS INHIBITOR; THROMBOSPONDIN 1;

ANAEROBIC BACTERIUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BIOACCUMULATION; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; DENSITY; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TRANSFER; HYPOXIA; IMMUNOHISTOCHEMISTRY; LIVER; LUNG METASTASIS; MALE; MELANOMA; MICROBIAL ATTENUATION; MICROVASCULATURE; MOUSE; MOUSE STRAIN; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; SALMONELLA CHOLERAESUIS; SPLEEN; SURVIVAL RATE; TISSUE SPECIFICITY; TRANSGENE; TUMOR VOLUME;

ANIMALS; BETA-GALACTOSIDASE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LAC OPERON; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SALMONELLA; SURVIVAL RATE; THROMBOSPONDIN 1; TRANSGENES;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; SALMONELLA CHOLERAESUIS;

EID: 13444303995     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700777     Document Type: Article

References (42)

1. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997;57:4537-4544.
2. Sznol M, Lin SL, Bermudes D, et al. Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest. 2000;105:1027-1030.
3. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol. 2003;4:548-556.
4. Lemmon MJ, van Zijl P, Fox ME, et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Therapy. 1997;4:791-796.
5. Theys J, Landuyt W, Nuyts S, et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther. 2001;8:294-297.
6. Dang LH, Bettegowda C, Huso DL, et al. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA. 2001;98:15155-15160.
7. Yazawa K, Fujimori M, Amano J, et al. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther. 2000;7:269-274.
8. Li X, Fu GF, Fan YR, et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 2003;10:105-111.
9. Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNF-α induction retain tumor-targeting in vivo. Nat Biotechnol. 1999;17: 37-41.
10. King I, Bermudes D, Lin S, et al. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum Gene Ther. 2002;13:1225-1233.
11. Nuyts S, Van Mellaert L, Theys J, et al. Radio-responsive recA promoter significantly increases TNF-α production in recombinant clostridia after 2 Gy irradiation. Gene Therapy. 2001;8:1197-1201.
12. Hartmann A, Kunz M, Kostlin S, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res. 1999;59:1578-1583.
13. Neitzel LT, Neitzel CD, Magee KL, Malafa MP. Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol. 1999;6:70-74.
14. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene. 2003;22:3172-3179.
15. Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factors-dependent and -independent mechanisms. Cancer Res. 2001;61:7830-7839.
16. Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental mental metastases via thrombospondin-1. Proc Natl Acad Sci USA. 1998;95:6343-6348.
17. Shiau AL, Chen YL, Liao CY, Huang YS, Wu CL. Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis. Vaccine. 2001;19: 3947-3956.
18. Lee CH, Wu CL, Shiau AL. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med. in press.
19. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992;99:683-690.
20. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
21. Weiss S, Chakraborty T. Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers. Curr Opin Biotechnol. 2001;12:467-472.
22. Critchley RJ, Jezzard S, Radford KJ, et al. Potential therapeutic applications of recombinant, invasive E. coli. Gene Therapy. 2004;11:1224-1233.
23. Grillot-Courvalin C, Goussard S, Courvalin P. Wild-type intracellular bacteria deliver DNA into mammalian cells. Cell Microbiol. 2002;4:177-186.
24. Bannerman DD, Tupper JC, Ricketts WA, Bennett CF, Winn RK, Harlan JM. A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis. J Biol Chem. 2001;276:14924-14932.
25. Dkhissi F, Lu H, Soria C, et al. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther. 2003;14:997-1008.
26. Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001;61:7669-7674.
27. Beecken WD, Fernandez A, Joussen AM, et al. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J Natl Cancer Inst. 2001;93:382-387.
28. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999;284:808-812.
29. Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H. Biology of tumor progression in human melanocytes. Lab Invest. 1987;56:461-474.
30. Straume O, Salvesen HB, Akslen LA. Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol. 1999;15:595-599.
31. Rodeck U, Becker D, Herlyn M. Basic fibroblast growth factor in human melanoma. Cancer Cells. 1991;3:308-311.
32. Potgens AJ, Lubsen NH, van Altena MC, Schoenmakers JG, Ruiter DJ, de Waal RM. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol. 1995;146:197-209.
33. Theys J, Landuyt W, Nuyts S, et al. Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol Med Microbiol. 2001;30:37-41.
34. Bleuel K, Popp S, Fusenig NE, Stanbridge EJ, Boukamp P. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci USA. 1999;96:2065-2070.
35. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol. 1999;155:441-452.
36. Lawler J. The functions of thrombospondin-1 and 2. Curr Opin Cell Biol. 2000;12:634-640.
37. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem. 2000;275:32167-32173.
38. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA. 2001;98:12485-12490.
39. Taraboletti G, Morbidelli L, Donnini S, et al. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J. 2000;14:1674-1676.
40. Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol. 2001;159:1949-1956.
41. Guo Y, Kyprianou N. Restoration of transforming growth factor-β signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res. 1999;59: 1366-1371.
42. Twardzik DR, Ranchalis JE, McPherson JM, et al. Inhibition and promotion of differentiated-like phenotype of a human lung carcinoma in athymic mice by natural and recombinant forms of transforming growth factor-β. J Natl Cancer Inst. 1989;81:1182-1185.